Please login to the form below

benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'. NICE has recommended the use of AstraZeneca’s severe asthma treatment Faserna (benralizumab) after the company revised its initial pricing offer. ... Benralizumab could offer an easier method of administration

Latest news

AZ says target of $45bn sales by 2023 still achievable

In respiratory, interleukin-5 inhibitor Fasenra (benralizumab) – which came to market after rival drugs from GlaxoSmithKline and Teva - is doing “extremely well”, said Soriot, capturing the lion’s share of new
Dupixent helps put Sanofi back on growth track

Fasenra (benralizumab) all jostling for market share.
FDA rejects GSK’s Nucala for COPD

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).
AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Tezepelumab is a thymic stromal lymphopoietin (TSLP) targeting antibody that would slot into AZ’s key respiratory portfolio alongside Fasenra (benralizumab), the company’s interleukin-5 inhibitor antibody, which was approved
New cancer drugs can’t quite plug the revenue hole at AZ

Fasenra (benralizumab) although overall respiratory sales were flat in the first half at $2.41bn.

More from news
Approximately 8 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Deal Watch March 2017

In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)
Pharma deals in July 2015

In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Health Policy – Global Agency: Salary TBC

Global Business Development Director – Health Education: excellent commission

Associate Director: £75, 000-90, 000

Account Director, Medical Education: Salary TBC

Account Manager / Account Director: Competative

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical Writer: Salary TBC

Senior Medical Writer: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Subscribe to our email news alerts

PMHub

Add my company

Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...